Antibody agonist for a G protein-coupled receptor as a treatment for pain in endometriosis
G 蛋白偶联受体抗体激动剂用于治疗子宫内膜异位症疼痛
基本信息
- 批准号:10482595
- 负责人:
- 金额:$ 29.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-10 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:Abdominal PainAcute PainAgonistAnalgesicsAnimal ModelAnimalsAnti-Inflammatory AgentsAntibodiesAntibody FormationAntibody TherapyAttenuatedAutologousB-LymphocytesBehaviorBiological AssayBlood - brain barrier anatomyBlood VesselsBronchiolesCNR1 geneCNR2 geneCell Culture TechniquesCell LineCellsChronicClinicalClinical ResearchClinical TrialsCognitiveDevelopmentDysmenorrheaEffectivenessEndometrialEpithelial CellsEstrogensExcisionFc ReceptorFibrosisFutureG-Protein-Coupled ReceptorsGTP-Binding Protein alpha Subunits, GsGenerationsGlandGoalsHumanIL8 geneImmuneImmunityIn VitroInfertilityInflammationInflammatoryInflammatory ResponseInterleukin-1 betaInterleukin-6LeadLesionLibrariesLiver FibrosisMeasuresMediatingMedical GeneticsMessenger RNAModelingMusMyofibroblastNeuropathyNociceptorsNon-Steroidal Anti-Inflammatory AgentsOperative Surgical ProceduresOpioidPainPain managementPatientsPelvic PainPeriodicityPeripheralPeritonealPhage DisplayPharmaceutical PreparationsPhaseProteinsRattusRodent ModelSymptomsSystemTNF geneTechnologyTestingTissuesTotal HysterectomyToxic effectUterusVariantViscosityWomanabaloneallodyniaantagonistchemotherapy induced neuropathychronic painful conditionchronic pelvic painclinical candidatecytokinecytokine release syndromedimerdrug efficacyendogenous cannabinoid systemendometriosisexperimental studyfirst-in-humangenetic associationimprovedin vivoinflammatory lung diseasemacrophagemanufacturabilitymouse modelmutantnanobodiesoff-label usepain modelpain reliefpainful neuropathypathogenprogramsreceptorresponseside effectsmall molecule
项目摘要
ABSTRACT
Endometriosis is a chronic, painful and debilitating gynecological condition associated with vascularized, fibrotic,
and innervated peritoneal lesions resembling endometrial glands, estimated to be present in ~50% of infertile
women and ~80% of women with chronic pelvic pain. Endometriosis symptoms such as cyclic and non-cyclic
pelvic pain and menstrual pain are thought to be associated with chronic peritoneal inflammation triggered by
the ectopic endometrial tissue. Surgical lesion removal and estrogen inhibition therapies are invasive, ineffective
long-term, or have severe and intolerable side effects. The most effective and lasting treatment for pain is
complete hysterectomy, which still has ~85% response rate. Painkillers, including opioids, and nonsteroidal anti-
inflammatory drugs are used off-label, but clinical studies do not support their effectiveness. Cannabinoid 2
receptors (CB2) are a promising target for endometriosis treatment. CB2 is most abundantly expressed in
immune cells, nociceptive neurons, and peripheral structural cells, notably epithelial cells and myofibroblasts,
including in uterine tissue. CB2 agonism (i.e., activation) reduces excess inflammation and fibrosis, but does not
impair beneficial inflammatory responses, such as anti-pathogen or adaptive humoral B-cell responses.
Beneficial for endometriosis, CB2 agonism is analgesic primarily in chronic pain conditions rather than in acute
pain. Several companies have developed small molecule CB2 agonists that, unfortunately, are rapidly cleared,
penetrate the blood-brain barrier and/or have off-target effects (notably cognitive ones) mediated by the CB1
receptor. Abalone Bio used its proprietary Functional Antibody Selection Technology (FAST) to isolate a
selective CB2-activating nanobody (VHH), which we converted into a VHH-Fc fusion lead antibody, ABt140, for
in vivo studies. ABt140 is expected to be a highly specific, long-lived, peripherally restricted CB2 receptor agonist
antibody (Ab) therapy for endometriosis, as a means of reverting or attenuating peritoneal inflammation and
fibrosis, and eliminating or reducing abdominal pain. Initial proof of concept has been achieved in mouse models
of pain, inflammation and fibrosis, specifically a model of chemotherapy-induced neuropathy, a model of
neuropathic pain that closely resembles human pain, a model of lung inflammatory disease and cytokine storm,
and a model of liver fibrosis. This Phase 1 project, with its 3 complementary and non-overlapping aims, will
advance our endometriosis program by, (1) validating in vitro our CB2 Ab agonist concept as an efficacious
strategy for painful endometriosis, (2) demonstrating that our drug’s efficacy in mouse is due to mechanisms of
action relevant to human endometriosis, and (3) improving the stability of our lead Ab to produce a commercially
and clinically viable candidate. If successful, additional animal models in a larger animal will be implemented,
further advancing Abalone’s antibody drug toward IND-enabling studies and first in human trials for painful
endometriosis.
摘要
子宫内膜异位症是一种慢性、疼痛和使人衰弱的妇科疾病,
和类似于子宫内膜腺体的神经支配的腹膜病变,估计存在于约50%的不孕症患者中,
约80%的女性患有慢性盆腔疼痛。子宫内膜异位症的症状如周期性和非周期性
盆腔痛和月经痛被认为与慢性腹膜炎有关,
异位子宫内膜组织手术切除病灶和雌激素抑制疗法是侵入性的,无效的
长期的,或有严重的和无法忍受的副作用。最有效和持久的治疗疼痛是
全子宫切除术,仍然有~85%的反应率。止痛药,包括阿片类药物和非甾体抗-
炎性药物被用于标签外,但临床研究并不支持其有效性。大麻素2
受体(CB 2)是子宫内膜异位症治疗的有希望的靶点。CB 2在以下组织中表达最丰富:
免疫细胞、伤害感受神经元和外周结构细胞,特别是上皮细胞和肌成纤维细胞,
包括子宫组织。CB 2激动作用(即,激活)减少过度炎症和纤维化,但不
削弱有益炎症反应,如抗病原体或适应性体液B细胞反应。
对于子宫内膜异位症有益的是,CB 2激动主要在慢性疼痛状况中而不是在急性疼痛状况中是镇痛的。
痛苦几家公司已经开发了小分子CB 2激动剂,不幸的是,这些激动剂被迅速清除,
穿透血脑屏障和/或具有由CB 1介导的脱靶效应(特别是认知效应)
受体的Abalone Bio使用其专有的功能性抗体选择技术(FAST)分离出一种
选择性CB 2激活纳米抗体(VHH),我们将其转化为VHH-Fc融合先导抗体ABt 140,用于
体内研究。ABt 140有望成为一种高特异性、长寿命、外周限制性CB 2受体激动剂
子宫内膜异位症的抗体(Ab)治疗,作为恢复或减弱腹膜炎症的手段,
纤维化和消除或减轻腹痛。在小鼠模型中实现了初步的概念验证
疼痛,炎症和纤维化的模型,特别是化疗诱导的神经病变的模型,
神经性疼痛与人类疼痛非常相似,是肺部炎症疾病和细胞因子风暴的模型,
和肝纤维化模型。该项目的第一阶段,其3个互补和不重叠的目标,将
推进我们的子宫内膜异位症计划,(1)在体外验证我们的CB 2 Ab激动剂概念作为一种有效的
疼痛性子宫内膜异位症的治疗策略,(2)证明我们的药物在小鼠中的疗效是由于
与人类子宫内膜异位症相关的作用,以及(3)提高我们的先导抗体的稳定性,以生产商业上
临床上可行的候选人。如果成功,将在更大的动物中实施额外的动物模型,
进一步推进Abalone的抗体药物的IND研究,并首次在人体试验中用于疼痛
子宫内膜异位症
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stacy L McAllister其他文献
Stacy L McAllister的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stacy L McAllister', 18)}}的其他基金
Targeting Reactive Aldehyde Metabolism in Endometriosis as a treatment strategy and a Diagnostic Biomarker
以子宫内膜异位症中的反应性醛代谢作为治疗策略和诊断生物标志物
- 批准号:
10214651 - 财政年份:2019
- 资助金额:
$ 29.29万 - 项目类别:
Targeting reactive aldehyde metabolism in endometriosis as a treatment strategy and a diagnostic biomarker
以子宫内膜异位症中的反应性醛代谢作为治疗策略和诊断生物标志物
- 批准号:
9432344 - 财政年份:2017
- 资助金额:
$ 29.29万 - 项目类别:
Targeting reactive aldehyde metabolism in endometriosis as a treatment strategy and a diagnostic biomarker
以子宫内膜异位症中的反应性醛代谢作为治疗策略和诊断生物标志物
- 批准号:
9572404 - 财政年份:2017
- 资助金额:
$ 29.29万 - 项目类别:
相似海外基金
Clinical Outcome Assessments for Acute Pain Therapeutics in Infants and young Children (COA APTIC)
婴幼儿急性疼痛治疗的临床结果评估 (COA APTIC)
- 批准号:
10778757 - 财政年份:2023
- 资助金额:
$ 29.29万 - 项目类别:
Selective actin remodeling of sensory neurons for acute pain management
感觉神经元的选择性肌动蛋白重塑用于急性疼痛管理
- 批准号:
10603436 - 财政年份:2023
- 资助金额:
$ 29.29万 - 项目类别:
Clinical Outcome Assessments for Acute Pain Therapeutics in Infants and young Children (COA APTIC)
婴幼儿急性疼痛治疗的临床结果评估 (COA APTIC)
- 批准号:
10783106 - 财政年份:2023
- 资助金额:
$ 29.29万 - 项目类别:
Development of A Focused Ultrasound Device for Noninvasive, Peripheral Nerve Blockade to Manage Acute Pain
开发用于非侵入性周围神经阻断来治疗急性疼痛的聚焦超声装置
- 批准号:
10740796 - 财政年份:2023
- 资助金额:
$ 29.29万 - 项目类别:
Predicting Pediatric Sickle Cell Disease Acute Pain Using Mathematical Models Based on mHealth Data
使用基于移动健康数据的数学模型预测儿童镰状细胞病急性疼痛
- 批准号:
10599401 - 财政年份:2022
- 资助金额:
$ 29.29万 - 项目类别:
Non-Contingent Acute Pain Stress Drives Analgesic Protection in Rats.
非偶然急性疼痛应激驱动大鼠镇痛保护。
- 批准号:
575854-2022 - 财政年份:2022
- 资助金额:
$ 29.29万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Master's
Prefrontal Cortex Hemodynamic Responses to Mindfulness Meditation and Acute Pain
前额皮质血流动力学对正念冥想和急性疼痛的反应
- 批准号:
467076 - 财政年份:2021
- 资助金额:
$ 29.29万 - 项目类别:
Studentship Programs
A Multimodal Approach for Monitoring Prolonged Acute Pain in Neonates
监测新生儿长期急性疼痛的多模式方法
- 批准号:
9979265 - 财政年份:2020
- 资助金额:
$ 29.29万 - 项目类别:
A Multimodal Approach for Monitoring Prolonged Acute Pain in Neonates
监测新生儿长期急性疼痛的多模式方法
- 批准号:
10218273 - 财政年份:2020
- 资助金额:
$ 29.29万 - 项目类别: